<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Chaudhuri, K. Ray</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">NMS in PD: Dopaminergic and Nondopaminergic</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-20</style></pages><abstract><style  face="normal" font="default" size="100%">The nonmotor symptoms (NMS) of Parkinson's disease (PD) are common and occur across all stages of disease. Often underreported and a key determinant of quality of life, they can occur in conjunction with nonmotor fluctuations (dysautonomic, cognitive/psychiatric, and sensory/pain). NMS in PD may be associated with dopamine deficiency due to degeneration of the substantia nigra, but they may have a nondopaminergic origin as well. This article discusses several of the PD-related NMS, management strategies for patients with PD with nondopaminergic NMS, and the emerging use of animal models to improve treatment of PD-related NMS and learn about early-onset NMS.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>